205 related articles for article (PubMed ID: 18237771)
1. Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo.
Taylor SA; Marrinan CH; Liu G; Nale L; Bishop WR; Kirschmeier P; Liu M; Long BJ
Gynecol Oncol; 2008 Apr; 109(1):97-106. PubMed ID: 18237771
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336).
Liu G; Marrinan CH; Taylor SA; Black S; Basso AD; Kirschmeier P; Robert Bishop W; Liu M; Long BJ
Anticancer Drugs; 2007 Sep; 18(8):923-31. PubMed ID: 17667598
[TBL] [Abstract][Full Text] [Related]
3. The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase.
Marcus AI; Zhou J; O'Brate A; Hamel E; Wong J; Nivens M; El-Naggar A; Yao TP; Khuri FR; Giannakakou P
Cancer Res; 2005 May; 65(9):3883-93. PubMed ID: 15867388
[TBL] [Abstract][Full Text] [Related]
4. Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models.
Liu G; Taylor SA; Marrinan CH; Hsieh Y; Bishop WR; Kirschmeier P; Long BJ
Int J Cancer; 2009 Dec; 125(11):2711-20. PubMed ID: 19530253
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of the farnesyltransferase inhibitor lonafarnib with weekly paclitaxel in patients with solid tumors.
Ready NE; Lipton A; Zhu Y; Statkevich P; Frank E; Curtis D; Bukowski RM
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):576-83. PubMed ID: 17255280
[TBL] [Abstract][Full Text] [Related]
6. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells.
Lee HY; Moon H; Chun KH; Chang YS; Hassan K; Ji L; Lotan R; Khuri FR; Hong WK
J Natl Cancer Inst; 2004 Oct; 96(20):1536-48. PubMed ID: 15494604
[TBL] [Abstract][Full Text] [Related]
7. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
Tang X; Lu M; Li C; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
[TBL] [Abstract][Full Text] [Related]
8. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
Choi HJ; Heo JH; Park JY; Jeong JY; Cho HJ; Park KS; Kim SH; Moon YW; Kim JS; An HJ
Gynecol Oncol; 2019 Apr; 153(1):135-148. PubMed ID: 30686552
[TBL] [Abstract][Full Text] [Related]
9. Lonafarnib for cancer and progeria.
Wong NS; Morse MA
Expert Opin Investig Drugs; 2012 Jul; 21(7):1043-55. PubMed ID: 22620979
[TBL] [Abstract][Full Text] [Related]
10. The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients.
Bachmann HS; Meier W; du Bois A; Kimmig R; Kuhlmann JD; Siffert W; Sehouli J; Wollschlaeger K; Huober J; Hillemanns P; Burges A; Schmalfeldt B; Aminossadati B; Wimberger P
Br J Clin Pharmacol; 2015 Nov; 80(5):1139-48. PubMed ID: 26033044
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors.
Khuri FR; Glisson BS; Kim ES; Statkevich P; Thall PF; Meyers ML; Herbst RS; Munden RF; Tendler C; Zhu Y; Bangert S; Thompson E; Lu C; Wang XM; Shin DM; Kies MS; Papadimitrakopoulou V; Fossella FV; Kirschmeier P; Bishop WR; Hong WK
Clin Cancer Res; 2004 May; 10(9):2968-76. PubMed ID: 15131032
[TBL] [Abstract][Full Text] [Related]
12. NSC23925 prevents the emergence of multidrug resistance in ovarian cancer in vitro and in vivo.
Yang X; Feng Y; Gao Y; Shen J; Choy E; Cote G; Harmon D; Zhang Z; Mankin H; Hornicek FJ; Duan Z
Gynecol Oncol; 2015 Apr; 137(1):134-42. PubMed ID: 25677062
[TBL] [Abstract][Full Text] [Related]
13. PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples.
Winterhoff B; Freyer L; Hammond E; Giri S; Mondal S; Roy D; Teoman A; Mullany SA; Hoffmann R; von Bismarck A; Chien J; Block MS; Millward M; Bampton D; Dredge K; Shridhar V
Eur J Cancer; 2015 May; 51(7):879-892. PubMed ID: 25754234
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.
Hu L; Hofmann J; Lu Y; Mills GB; Jaffe RB
Cancer Res; 2002 Feb; 62(4):1087-92. PubMed ID: 11861387
[TBL] [Abstract][Full Text] [Related]
15. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
[TBL] [Abstract][Full Text] [Related]
16. Nsc23925 prevents the development of paclitaxel resistance by inhibiting the introduction of P-glycoprotein and enhancing apoptosis.
Yang X; Shen J; Gao Y; Feng Y; Guan Y; Zhang Z; Mankin H; Hornicek FJ; Duan Z
Int J Cancer; 2015 Oct; 137(8):2029-39. PubMed ID: 25904021
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the in vitro activity of AZD3409, a novel prenyl transferase inhibitor.
Appels NM; Bolijn MJ; van Eijndhoven MA; Stephens TC; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2011 Jan; 67(1):137-45. PubMed ID: 20229082
[TBL] [Abstract][Full Text] [Related]
18. The farnesyltransferase inhibitor Lonafarnib induces growth arrest or apoptosis of human lung cancer cells without downregulation of Akt.
Sun SY; Zhou Z; Wang R; Fu H; Khuri FR
Cancer Biol Ther; 2004 Nov; 3(11):1092-8; discussion 1099-1101. PubMed ID: 15467440
[TBL] [Abstract][Full Text] [Related]
19. CXCR4 blockade with AMD3100 enhances Taxol chemotherapy to limit ovarian cancer cell growth.
Reeves PM; Abbaslou MA; Kools FRW; Poznansky MC
Anticancer Drugs; 2017 Oct; 28(9):935-942. PubMed ID: 28817386
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter?
Modesitt SC; Parsons SJ
Gynecol Oncol; 2010 Nov; 119(2):351-7. PubMed ID: 20673975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
